President Donald Trump has directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.

President Donald Trump signed an executive order allowing the use of some psychedelic drugs to treat post-traumatic stress disorder. Flanked by Health and Human Services Secretary Robert F. Kennedy Jr ...

The US president said his directive will help "dramatically accelerate" access to research and treatments on psychedelic ...

The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the ...

President Donald Trump has signed an executive order aimed at speeding up research and access to psychedelic drugs as potential treatments for serious mental health conditions. The move directs ...

Executive order to speed access to psychedelic treatments likely to have limited legal impact despite high-profile push ...

By Kamal Choudhury and Christy Santhosh April 24 (Reuters) - The U.S. health regulator on Friday moved to speed up the development of new treatments for serious mental illness by awarding the national ...

Like this article? Keep independent journalism alive. Support HuffPost. The Food and Drug Administration has announced efforts to expedite its research into perception-altering psychedelic medications ...

The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the ...

The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help treat post-traumatic stress disorder.